Clinical Oncology NewsSpotlight on selected articles from the Journal of Clinical Oncology and BloodClinical Oncology NewsAnas Younes, MD; Yvette Kasamon, MD; and colleagues took advantage of the CD-20 expression in classical Hodgkin's lymphoma (cH…
Rituximab Useful in Idiopathic Membranous NephropathyDoctors LoungeFor patients with idiopathic membranous nephropathy and persistent nephrotic syndrome, rituximab treatment is associated with good rates of partial or complete remission with stabilized…
Gilead Sciences Management Discusses Q2 2012 Results – Earnings Call …Seeking AlphaThese studies in a placebo-controlled fashion compare GS-1101 added to either Rituximab or to Rituximab with Bendamustine in relapsed refractory CLL patient. My remain…
Spectrum Pharmaceuticals Announces Publication Demonstrating Enhanced …Business Wire (press release)The data, published in Blood, the journal of the American Society of Hematology, showed that addition of ZEVALIN following fludarabine, cyclophosphami…
Immune Drug Helps Patients with Serious Kidney DisorderNewswise (press release)Because the drug rituximab specifically targets immune cells involved in the development and progression of IMN, Piero Ruggenenti, MD, Giuseppe Remuzzi, MD, FRCP (Mario Negr…
Dendreon Reports Q2 Earnings On July 30Seeking Alpha… Spectrum Pharmaceuticals Inc announced the initiation of a Phase II study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolini…
OncLivePlenary Sunday at ASCOOncLiveBendamustine—an alkylating agent developed at that time—combined with rituximab produced superior outcomes and fewer toxicities than CHOP plus rituximab in patients with indolent and mantle cell lymphomas. Last b…
Spectrum Pharmaceuticals Announces Publication Demonstrating Enhanced …MarketWatch (press release)The data, published in Blood, the journal of the American Society of Hematology, showed that addition of ZEVALIN following fludarabine, cyclophosphamide…
BloombergBiogen Idec Q2 profits rise on strong Avonex salesPMLiVEEnrolment has been completed in the DECIDE trial of another MS drug candidate, daclizumab, with results expected in 2014, said Williams, while a phase IIa trial has got underway for STX-1…
Biogen Idec 2nd-qtr sales and earnings top analysts expectationsThe Pharma Letter… global pediatric studies for its long-lasting factor VIII and factor IX programs for hemophilia and completing enrollment in the Phase III A-LONG and B-LONG trials for…